Cancer: Vol 130, No 24
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Related Articles
MT-302 Utilizes Novel Mechanism of Action to Offer a Unique Treatment in Epithelial Tumors
Rasha Cosman, BSc, MBBS, FRACP, and Charlotte Lemech, MBBS, discuss the phase 1 MYE Symphony study (NCT05969041) of MT-302 in advanced or metastatic epithelial cancers.
Behind the Phase 1 Study of TAR-210 in FGFR-Altered NMIBC
Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and…
Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma
Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.
Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
Oncology Overdrive | 2024 Episodes | Healio Podcasts
A podcast hosted by Shikha Jain, MD, FACP, covering modern day health care in an ever-evolving world. Watch 2024 episodes on Healio today.
Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.
Voice-Based Screening May Predict Risk of Major Depression : Oncology Times
An abstract is unavailable.
FDA Accepts BLA for Belantamab Mafodotin Combinations in R/R Multiple Myeloma
The FDA has accepted the BLA for belantamab mafodotin in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma, as supported…
FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma
The FDA accepted a BLA for 2 belantamab mafodotin–based combinations in relapsed/refractory multiple myeloma.